KZR NASDAQ
Kezar Life Sciences, Inc.
1W: -1.4%
1M: -1.1%
3M: +18.5%
YTD: +15.9%
1Y: +76.9%
3Y: -97.2%
5Y: -98.7%
$7.29
Last traded 2026-05-11 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
14 relationships13
As Filer
counterparties named
1
As Counterparty
mentioned by others
3
Rel. Types
2021-11-09
Earliest Filing
2026-04-03
Latest Filing
partner: 7
acquirer: 5
investor: 1
Counterparties (Filed by KZR)
13 relationshipsCompanies named in KZR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Aurinia Pharma U.S., Inc. | — | acquirer | Parent company entering Agreement and Plan of Merger to acquire Kezar Life Sciences, Inc. | 2026-03-30 | View |
| Aurinia Merger Sub, Inc. | — | acquirer | Wholly owned subsidiary of Aurinia Pharma U.S., Inc. entering Agreement and Plan of Merger to acquire Kezar Life Science | 2026-03-30 | View |
| Aurinia Pharmaceuticals Inc. | AUPH | acquirer | Ultimate parent company of Aurinia Pharma U.S., Inc. entering Agreement and Plan of Merger. | 2026-03-30 | View |
| Enodia Therapeutics SAS | — | partner | Counterparty to an existing Asset Purchase Agreement referenced in the Contingent Value Rights Agreement. | 2026-03-30 | View |
| Everest Medicines II (HK) Limited | — | partner | Counterparty to an existing Collaboration and License Agreement referenced in the Contingent Value Rights Agreement. | 2026-03-30 | View |
| Tang Capital Partners, LP | — | investor | Supporting stockholder entering a Tender and Support Agreement to tender shares in the merger offer. | 2026-03-30 | View |
| Enodia Therapeutics SAS | — | acquirer | Acquired all rights to Kezar Life Sciences' Sec61-based discovery and development program assets including KZR-261. | 2026-03-12 | View |
| Computershare Trust Company, N.A. | — | partner | Serves as Rights Agent and transfer agent for the Rights Agreement. | 2024-10-17 | View |
| Concentra Biosciences, LLC | — | acquirer | Made an unsolicited, non-binding proposal to acquire all outstanding shares of Company Common Stock. | 2024-10-17 | View |
| Everest Medicines II (HK) Limited | — | partner | Exclusive licensee for development and commercialization of zetomipzomib in Greater China, South Korea, and Southeast As | 2023-09-21 | View |
| Everest Medicines Limited | — | partner | Guarantor for Everest Medicines II (HK) Limited's obligations under the License Agreement. | 2023-09-21 | View |
| Cowen and Company, LLC | — | partner | Sales agent for at-the-market offering program | 2021-11-19 | View |
| Capital Advisors Group, Inc | — | partner | Financial advisor to Kezar Life Sciences, Inc. for the credit facility. | 2021-11-09 | View |
Mentioned As Counterparty
1 mentionsOther companies that named KZR in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-04-03 | Termination of Agreement; Officer/Director Change; Exhibits | View | |
| 2026-03-30 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-03-12 | Entry into Material Definitive Agreement; Completion of Acquisition or Disposition of Assets; Regula | Agreement Acquisition | View |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-07 | Costs Associated with Exit or Disposal Activities | View | |
| 2025-10-22 | Termination of Material Definitive Agreement | View | |
| 2025-10-16 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Material Mo | Agreement | View |
| 2025-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-23 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-01 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-03-25 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-02-27 | Other Events; Financial Statements and Exhibits | View | |
| 2025-01-10 | Results of Operations and Financial Condition | View | |
| 2024-12-03 | Entry into Material Definitive Agreement; Material Modification to Rights of Security Holders | Agreement | View |
| 2024-11-14 | Notice of Delisting or Transfer | View | |
| 2024-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-28 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2024-10-17 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Material Mo | Agreement | View |
| 2024-10-10 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR